In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in balb/c mice

被引:178
作者
Griffiths, EA
Duffy, LC
Schanbacher, FL
Qiao, HP
Dryja, D
Leavens, A
Rossman, J
Rich, G
Dirienzo, D
Ogra, PL
机构
[1] SUNY Buffalo, Women & Childrens Hosp Buffalo, Dept Pediat, Kaleida Hlth, Buffalo, NY 14260 USA
[2] SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA
[3] Ohio State Univ, Ohio Agr Res & Dev Ctr, Dept Anim Sci, Labs Mol & Dev Biol, Wooster, OH 44691 USA
[4] Dairy Management Inc, Natl Dairy Council, Rosemont, IL USA
关键词
bifidobacteria; lactoferrin; probiotics; endotoxin; mucosal immunity;
D O I
10.1023/B:DDAS.0000026302.92898.ae
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The aim of the present study was to examine the effects of oral supplementation of newborn Balb/c mice with bifidobacteria (B. infantis, B. bifidum) and iron-free apo-lactoferrin (bovine, human) on gut endotoxin concentration and mucosal immunity. Endotoxin concentration was measured in ileocecal filtrates at 7, 14, 21, and 28 days postdelivery by a quantitative limulus amebocyte lysate test. While endotoxin levels in bifidobacteria-fed mice showed a steady rise over time, they were consistently lower than that observed in control animals. Results of lactoferrin supplementation varied depending on the specific time point, but overall by day 28, all treatment groups showed lower intestinal endotoxin concentrations compared to saline fed animals. Neither bifidobacteria nor lactoferrin stimulated an increase in B or T cells, or in cytokine production (IL-6, TNF-alpha, INF-gamma), in Peyer's patches as measured by flow cytometry. Bifidobacteria and lactoferrin were well tolerated as dietary supplements and showed promising potential to reduce gut endotoxin levels.
引用
收藏
页码:579 / 589
页数:11
相关论文
共 75 条
[1]   LACTOFERRIN IS A LIPID A-BINDING PROTEIN [J].
APPELMELK, BJ ;
AN, YQ ;
GEERTS, M ;
THIJS, BG ;
DEBOER, HA ;
MACLAREN, D ;
DEGRAAFF, J ;
NUIJENS, JH .
INFECTION AND IMMUNITY, 1994, 62 (06) :2628-2632
[2]   BACTERICIDAL ACTIVITY OF HUMAN LACTOFERRIN - DIFFERENTIATION FROM THE STASIS OF IRON DEPRIVATION [J].
ARNOLD, RR ;
RUSSELL, JE ;
CHAMPION, WJ ;
BREWER, M ;
GAUTHIER, JJ .
INFECTION AND IMMUNITY, 1982, 35 (03) :792-799
[3]   THE INTESTINAL MICROFLORA OF INFANTS - COMPOSITION OF FECAL FLORA IN BREAST-FED AND BOTTLE-FED INFANTS [J].
BENNO, Y ;
SAWADA, K ;
MITSUOKA, T .
MICROBIOLOGY AND IMMUNOLOGY, 1984, 28 (09) :975-986
[4]   ADHESION OF HUMAN BIFIDOBACTERIAL STRAINS TO CULTURED HUMAN INTESTINAL EPITHELIAL-CELLS AND INHIBITION OF ENTEROPATHOGEN-CELL INTERACTIONS [J].
BERNET, MF ;
BRASSART, D ;
NEESER, JR ;
SERVIN, AL .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1993, 59 (12) :4121-4128
[5]   INVITRO GROWTH-INHIBITION OF MASTITIS-CAUSING COLIFORM BACTERIA BY BOVINE APO-LACTOFERRIN AND REVERSAL OF INHIBITION BY CITRATE AND HIGH-CONCENTRATIONS OF APO-LACTOFERRIN [J].
BISHOP, JG ;
SCHANBACHER, FL ;
FERGUSON, LC ;
SMITH, KL .
INFECTION AND IMMUNITY, 1976, 14 (04) :911-918
[6]   Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans [J].
Bouhnik, Y ;
Vahedi, K ;
Achour, L ;
Attar, A ;
Salfati, J ;
Pochart, P ;
Marteau, P ;
Flourié, B ;
Bornet, F ;
Rambaud, JC .
JOURNAL OF NUTRITION, 1999, 129 (01) :113-116
[7]   History of oral tolerance and mucosal immunity [J].
Brandtzaeg, P .
ORAL TOLERANCE: MECHANISMS AND APPLICATIONS, 1996, 778 :1-27
[9]  
BULLEN JJ, 1975, POSTGRAD MED J, V51, P67
[10]   LACTOFERRIN IN INFANT FORMULAS [J].
CHIERICI, R ;
VIGI, V .
ACTA PAEDIATRICA, 1994, 83 :83-88